H.C. Wainwright lowered the firm’s price target on KalVista (KALV) to $27 from $30 and keeps a Buy rating on the shares. The firm says a recurring concern in its talks with key opinion leaders is the challenge facing KalVista of securing insurance coverage for Ekterly. The leaders would lack a strong clinical argument to justify Ekterly as medically superior if coverage were denied, given the absence of head-to-head data showing superiority over existing on-demand options like icatibant, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista price target raised to $37 from $22 at BofA
- KalVista price target raised to $27 from $19 at Citizens JMP
- KalVista price target raised to $20 from $18 at Leerink
- Buy Rating for KalVista Pharmaceuticals Driven by FDA Approval and Strategic Market Entry of Ekterly
- KalVista price target raised to $40 from $32 at Jefferies